Published in Drug Week, September 9th, 2005
"We are committed to expanding our data on Advate with extensive follow-up clinical investigations and analyses of this product in a variety of medical settings," said Bruce Ewenstein, MD, PhD, global medical director for hemophilia therapies at Baxter. "These two studies echo the results of our original...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.